Previous 10 | Next 10 |
Company’s Lead Joint Researcher Professor Perán to Present Latest PRP Research Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients s...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Fou...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced significant effects of PRP against the t...
A Backup Clinical Candidate Could Provide Additional Benefits for Projected $111 Global Metastatic Cancer Market Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatm...
Propanc Biopharma ( OTCQB:PPCB ) said it received a notice of allowance from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer. The company added that it was its second patent application allowed in this jurisdiction and expir...
The Second Patent Application Allowed with a Third Under Examination in Europe Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from r...
Research Evaluates Effects of Against the Tumor Microenvironment Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and m...
Five Scientific Publications Underscores Proenzymes as an Effective Tool to Treat and Prevent Metastatic Cancer from Solid Tumors with Further Research in Progress Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a bioph...
Identifying a Backup Clinical Candidate for Projected $111B Global Metastatic Cancer Market Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suf...
Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that CEO and Co-Founder Mr. James Nathaniel...
News, Short Squeeze, Breakout and More Instantly...
Propanc Biopharma Inc Company Name:
PPCB Stock Symbol:
OTCMKTS Market:
Propanc Biopharma Inc Website:
British Journal of Cancer Concludes Tumor cell-intrinsic PD-L1 function promotes EMT Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recu...
Certificate of Grant Received for “Cancer Treatment” Patent from IP Corporation of Malaysia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patient...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s &...